Fundraising FoxImmusoft
Seattle, US · Delaware corporation · 16 known investors
Find your way into Immusoft
Each arrow is one introduction. Sign up to fill in the first one.
Ask Julia Moore to introduce you to Matthew Scholz
You →Julia · together at Immusoft →Matthew
Ask Jamie Chen to introduce you to Sean Ainsworth
You →Jamie · together at RetroSense Therapeutics →Sean
Sign up to find every way you can get introduced to Immusoft
- Your email: who you already know at Immusoft, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Immusoft team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.
Founders & leadership
Board
Investors · 16
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Boston Harbor Angels's portfolio page · Not right? Tell us
How we know: Breakout Ventures's portfolio page · immusoft.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RV Invest GmbH's portfolio page · Not right? Tell us
How we know: Taihill Venture's portfolio page · Not right? Tell us
How we know: immusoft.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$40.5M disclosed across 6 of 9 rounds · 2014–2026
- Undisclosed amountSeries BJan 2019
Alexandria Venture Investments, Breakout Ventures, DEFTA Partners, Mesa Verde Venture Partners, RBV Capital
Source ↗
▶$4.6MraisedJun 2024 · 25 investors · OtherRule 506(b)
- Julia MooreDirector
- Sean AinsworthExecutive Officer, Director
- Matthew ScholzDirector
- Cam GallahgerDirector
- Anthony SunDirector
- Offering amount
- $10M
- Amount sold
- $4.6M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedMar 2021 · 32 investors · OtherRule 506(b)
- Anthony SunDirector
- Julia MooreDirector
- Wendell KingDirector
- Sean c/o AinsworthExecutive Officer, Director
- Matthew ScholzDirector
- Offering amount
- $11M
- Amount sold
- $10.3M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedJan 2019 · 64 investors · OtherRule 506(b)
- Sean AinsworthExecutive Officer, Director
- Julia MooreDirector
- Wendell KingDirector
- Anthony SunDirector
- Matthew ScholzDirector
- Rich VincentExecutive Officer
- Offering amount
- $23.4M
- Amount sold
- $20.2M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedNov 2016 · 11 investors · OtherRule 506(b)
- Mark Ahn, Ph.D.Director
- Wendell KingDirector
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $2.7M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$375KraisedAug 2015 · 3 investors · BiotechnologyRule 506(b)
- Matthew ScholzExecutive Officer, Director
- Mark Ahn, Ph.D.Director
- Offering amount
- $1M
- Amount sold
- $375K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedAug 2014 · 11 investors · BiotechnologyRule 506(b)
- Richard Chin, M.D.Director
- Eric GarciaExecutive Officer
- Matthew ScholzExecutive Officer, Director
- Mark Ahn, Ph.D.Director
- Offering amount
- $3.3M
- Amount sold
- $2.4M
- First sale
- Aug 2014
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Immusoft went on to found or lead other companies.
Related companies · 6
Companies working in the same space as Immusoft.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $466.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $3.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immusoft do?
- Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.
- Who founded Immusoft?
- Immusoft was founded by Matthew Scholz.
- Who are Immusoft's investors?
- Immusoft's investors include BioRock Ventures, Boston Harbor Angels, Breakout Ventures, EQx Fund, Invariantes Fund, Michigan Capital Network, NYBC Ventures, RV Invest GmbH and 5 more.
- How much funding has Immusoft raised?
- Immusoft has disclosed $40.5M raised across 6 of its 9 known rounds.
- Where is Immusoft headquartered?
- Immusoft is headquartered in Seattle, US.